Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:boron group molecular entity
go back to main search page
Accession:CHEBI:33581 term browser browse the term
Synonyms:related_synonym: boron group molecular entities


show annotations for term's descendants           Sort by:
 
2-[4-[(E)-2-(6,8-dichloro-2-phenyl-2H-chromen-3-yl)ethenyl]phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nphs1 NPHS1 adhesion molecule, nephrin increases expression ISO BD4 increases expression of Nphs1 mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
JBrowse link
G Synpo synaptopodin increases expression ISO BD4 increases expression of Synpo mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126
JBrowse link
2-aminoethoxydiphenylborane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] CTD PMID:29883672 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] CTD PMID:29883672 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Casp12 caspase 12 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] CTD PMID:29883672 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp3 caspase 3 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] CTD PMID:29883672 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cd28 Cd28 molecule multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] CTD PMID:14607919 NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
JBrowse link
G Grm1 glutamate metabotropic receptor 1 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] CTD PMID:14622174 NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein] CTD PMID:33408296 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport ISO ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene CTD PMID:12739759 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
aluminium hydroxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression EXP Aluminum Hydroxide results in decreased expression of ABCC2 protein CTD PMID:14976346 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 PMID:22075093 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Cat catalase decreases activity EXP Aluminum Hydroxide results in decreased activity of CAT protein CTD PMID:14976346 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL2 protein CTD PMID:18390722 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL3 protein CTD PMID:18390722 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL4 protein CTD PMID:18390722 NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL5 protein CTD PMID:18390722 NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
JBrowse link
G Ccr7 C-C motif chemokine receptor 7 multiple interactions ISO Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein] CTD PMID:18390722 NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
JBrowse link
G Cd14 CD14 molecule decreases expression ISO Aluminum Hydroxide results in decreased expression of CD14 protein CTD PMID:18390722 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
JBrowse link
G Cd4 Cd4 molecule affects response to substance ISO CD4 protein affects the susceptibility to Aluminum Hydroxide CTD PMID:11160013 NCBI chr 4:157,668,878...157,695,366 JBrowse link
G Cd40 CD40 molecule increases expression ISO Aluminum Hydroxide results in increased expression of CD40 protein CTD PMID:11160013 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd80 Cd80 molecule multiple interactions ISO Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein] CTD PMID:18390722 NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
JBrowse link
G Cd83 CD83 molecule increases expression ISO Aluminum Hydroxide results in increased expression of CD83 protein CTD PMID:11160013 NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
JBrowse link
G Cd86 CD86 molecule increases expression
multiple interactions
ISO Aluminum Hydroxide results in increased expression of CD86 protein
Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]
CTD PMID:11160013 PMID:18390722 NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
JBrowse link
G Chrna4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions ISO Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] CTD PMID:22750351 NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
JBrowse link
G Chrnb2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] CTD PMID:22750351 NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]; Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein] CTD PMID:18390722 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO [Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein] CTD PMID:17404311 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression ISO Aluminum Hydroxide results in increased expression of ICAM1 protein CTD PMID:11160013 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Il13 interleukin 13 increases expression ISO Aluminum Hydroxide results in increased expression of IL13 mRNA CTD PMID:9328138 NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
CTD PMID:17404311 PMID:18604214 PMID:22075093 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
JBrowse link
G Il1rn interleukin 1 receptor antagonist increases secretion ISO Aluminum Hydroxide results in increased secretion of IL1RN protein CTD PMID:18390722 NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
JBrowse link
G Il2 interleukin 2 increases expression
multiple interactions
ISO Aluminum Hydroxide results in increased expression of IL2 mRNA
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]
CTD PMID:9328138 PMID:22075093 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il4 interleukin 4 increases expression
affects response to substance
multiple interactions
ISO Aluminum Hydroxide results in increased expression of IL4 mRNA
IL4 protein affects the susceptibility to Aluminum Hydroxide
Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]
CTD PMID:9328138 PMID:11160013 PMID:18390722 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il5 interleukin 5 increases expression ISO Aluminum Hydroxide results in increased expression of IL5 mRNA CTD PMID:9328138 NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
JBrowse link
G Il6 interleukin 6 increases expression ISO Aluminum Hydroxide results in increased expression of IL6 mRNA CTD PMID:9328138 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
JBrowse link
G Pycard PYD and CARD domain containing multiple interactions ISO PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
JBrowse link
G Tfrc transferrin receptor multiple interactions ISO Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein] CTD PMID:18390722 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide] CTD PMID:22075093 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
aluminium ion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hmbs hydroxymethylbilane synthase decreases activity EXP Aluminium ion decreases activity of purified Hmbs protein RGD PMID:6732900 RGD:25394584 NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
JBrowse link
aluminium oxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acp5 acid phosphatase 5, tartrate resistant decreases expression ISO Aluminum Oxide results in decreased expression of ACP5 mRNA CTD PMID:15585240 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
JBrowse link
G Actr2 actin related protein 2 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ACTR2 protein CTD PMID:25598225 NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524
JBrowse link
G Alpl alkaline phosphatase, biomineralization associated increases expression ISO Aluminum Oxide results in increased expression of ALPL mRNA CTD PMID:19464052 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
JBrowse link
G Bcl2l1 Bcl2-like 1 increases expression ISO Aluminum Oxide analog results in increased expression of BCL2L1 mRNA CTD PMID:23132795 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO Aluminum Oxide results in increased expression of BGLAP mRNA CTD PMID:19464052 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Bgn biglycan increases expression ISO Aluminum Oxide results in increased expression of BGN mRNA CTD PMID:19464052 NCBI chr  X:151,197,296...151,209,458
Ensembl chr  X:151,197,273...151,209,461
JBrowse link
G Bmp1 bone morphogenetic protein 1 increases expression ISO Aluminum Oxide results in increased expression of BMP1 mRNA CTD PMID:19464052 NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
JBrowse link
G Bmp2 bone morphogenetic protein 2 increases expression ISO Aluminum Oxide results in increased expression of BMP2 mRNA CTD PMID:19464052 NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
JBrowse link
G Bmp4 bone morphogenetic protein 4 increases expression ISO Aluminum Oxide results in increased expression of BMP4 mRNA CTD PMID:19464052 NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
JBrowse link
G Bmp6 bone morphogenetic protein 6 decreases expression ISO Aluminum Oxide results in decreased expression of BMP6 mRNA CTD PMID:19464052 NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
JBrowse link
G C3 complement C3 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of C3 protein CTD PMID:25598225 NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
JBrowse link
G Camp cathelicidin antimicrobial peptide multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CAMP protein CTD PMID:25598225 NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
JBrowse link
G Casp3 caspase 3 increases expression ISO Aluminum Oxide results in increased expression of CASP3 CTD PMID:21329562 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase increases activity EXP Aluminum Oxide results in increased activity of CAT protein CTD PMID:22161306 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion ISO Aluminum Oxide results in increased secretion of CCL2 protein CTD PMID:17618502 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Cd14 CD14 molecule multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CD14 protein CTD PMID:25598225 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
JBrowse link
G Cd36 CD36 molecule increases expression ISO Aluminum Oxide results in increased expression of CD36 mRNA CTD PMID:19464052 NCBI chr 4:17,317,343...17,410,084 JBrowse link
G Cdh11 cadherin 11 increases expression ISO Aluminum Oxide results in increased expression of CDH11 mRNA CTD PMID:19464052 NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO Aluminum Oxide analog results in increased expression of CDKN1A mRNA CTD PMID:23132795 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Clu clusterin multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CLU protein CTD PMID:25598225 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
JBrowse link
G Col10a1 collagen type X alpha 1 chain increases expression ISO Aluminum Oxide results in increased expression of COL10A1 mRNA CTD PMID:19464052 NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression ISO Aluminum Oxide results in increased expression of COL11A1 mRNA CTD PMID:19464052 NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
JBrowse link
G Col15a1 collagen type XV alpha 1 chain increases expression ISO Aluminum Oxide results in increased expression of COL15A1 mRNA CTD PMID:19464052 NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of COL1A1 protein CTD PMID:12209937 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression ISO Aluminum Oxide results in increased expression of COL1A2 mRNA CTD PMID:19464052 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Comp cartilage oligomeric matrix protein increases expression ISO Aluminum Oxide results in increased expression of COMP mRNA CTD PMID:19464052 NCBI chr16:19,047,206...19,055,584
Ensembl chr16:19,047,207...19,055,845
JBrowse link
G Csf2 colony stimulating factor 2 increases secretion ISO Aluminum Oxide results in increased secretion of CSF2 protein CTD PMID:15046894 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Ctsk cathepsin K increases expression ISO Aluminum Oxide results in increased expression of CTSK mRNA CTD PMID:19464052 NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
JBrowse link
G Egfr epidermal growth factor receptor increases expression ISO Aluminum Oxide results in increased expression of EGFR mRNA CTD PMID:19464052 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Fgb fibrinogen beta chain multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of FGB protein CTD PMID:25598225 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression ISO Aluminum Oxide results in increased expression of FLT1 mRNA CTD PMID:19464052 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
JBrowse link
G Fn1 fibronectin 1 increases expression ISO Aluminum Oxide results in increased expression of FN1 mRNA CTD PMID:19464052 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Aluminum Oxide results in decreased expression of FOS mRNA CTD PMID:15585240 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Gsr glutathione-disulfide reductase decreases activity EXP Aluminum Oxide results in decreased activity of GSR protein CTD PMID:22161306 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Ibsp integrin-binding sialoprotein increases expression ISO Aluminum Oxide results in increased expression of IBSP mRNA CTD PMID:19464052 NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression ISO Aluminum Oxide results in increased expression of ICAM1 protein CTD PMID:18456438 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Igf1 insulin-like growth factor 1 affects expression ISO Aluminum Oxide affects the expression of IGF1 mRNA CTD PMID:19464052 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Il10 interleukin 10 increases expression ISO Aluminum Oxide results in increased expression of IL10 mRNA CTD PMID:15183442 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il1a interleukin 1 alpha increases expression ISO Aluminum Oxide results in increased expression of IL1A mRNA CTD PMID:15183442 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
JBrowse link
G Il1b interleukin 1 beta increases expression
increases secretion
multiple interactions
ISO Aluminum Oxide results in increased expression of IL1B mRNA
Aluminum Oxide results in increased secretion of IL1B protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in decreased secretion of IL1B protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
[Aluminum Oxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
CTD PMID:15183442 PMID:16488289 PMID:17618502 PMID:25216247 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
decreases secretion
ISO Aluminum Oxide results in increased expression of IL6 mRNA; Aluminum Oxide results in increased expression of IL6 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of IL6 protein
Aluminum Oxide results in decreased secretion of IL6 protein
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL6 protein]
CTD PMID:11771709 PMID:25216247 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Itga1 integrin subunit alpha 1 increases expression ISO Aluminum Oxide results in increased expression of ITGA1 mRNA CTD PMID:19464052 NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
JBrowse link
G Itga3 integrin subunit alpha 3 increases expression ISO Aluminum Oxide results in increased expression of ITGA3 mRNA CTD PMID:19464052 NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
JBrowse link
G Itga5 integrin subunit alpha 5 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGA5 protein CTD PMID:12209937 NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGB1 protein CTD PMID:12209937 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
JBrowse link
G Itih4 inter-alpha-trypsin inhibitor heavy chain 4 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ITIH4 protein CTD PMID:25598225 NCBI chr16:6,080,539...6,095,710
Ensembl chr16:6,080,539...6,095,708
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Aluminum Oxide results in increased expression of JUN mRNA CTD PMID:16488289 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LCN2 protein CTD PMID:25598225 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
JBrowse link
G Ltf lactotransferrin multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LTF protein CTD PMID:25598225 NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
JBrowse link
G Mmp1 matrix metallopeptidase 1 increases expression ISO Aluminum Oxide results in increased expression of MMP1 mRNA CTD PMID:16488289 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression ISO Aluminum Oxide results in increased expression of MMP2 mRNA CTD PMID:14661256 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression ISO Aluminum Oxide results in increased expression of MMP3 mRNA CTD PMID:16488289 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
JBrowse link
G Mmp8 matrix metallopeptidase 8 decreases expression ISO Aluminum Oxide results in decreased expression of MMP8 mRNA CTD PMID:19464052 NCBI chr 8:4,724,009...4,732,956
Ensembl chr 8:4,724,029...4,733,520
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression ISO Aluminum Oxide results in increased expression of MMP9 mRNA CTD PMID:16488289 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of MPO protein CTD PMID:25598225 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Pdgfa platelet derived growth factor subunit A increases expression ISO Aluminum Oxide results in increased expression of PDGFA mRNA CTD PMID:19464052 NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
JBrowse link
G Phex phosphate regulating endopeptidase homolog, X-linked increases expression ISO Aluminum Oxide results in increased expression of PHEX mRNA CTD PMID:19464052 NCBI chr  X:37,607,553...37,856,183
Ensembl chr  X:37,610,760...37,854,469
JBrowse link
G Ptk2 protein tyrosine kinase 2 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of PTK2 protein CTD PMID:12209937 NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A8 protein CTD PMID:25598225 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
JBrowse link
G S100a9 S100 calcium binding protein A9 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A9 protein CTD PMID:25598225 NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
JBrowse link
G Scarb1 scavenger receptor class B, member 1 decreases expression ISO Aluminum Oxide results in decreased expression of SCARB1 mRNA CTD PMID:19464052 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
JBrowse link
G Sele selectin E increases expression ISO Aluminum Oxide results in increased expression of SELE protein CTD PMID:18456438 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
JBrowse link
G Serpinh1 serpin family H member 1 increases expression ISO Aluminum Oxide results in increased expression of SERPINH1 mRNA CTD PMID:19464052 NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein; [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein alternative form CTD PMID:12209937 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
JBrowse link
G Sp7 Sp7 transcription factor increases expression ISO Aluminum Oxide results in increased expression of SP7 mRNA CTD PMID:19464052 NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression
multiple interactions
decreases secretion
ISO Aluminum Oxide results in increased expression of SPP1 mRNA
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of SPP1 protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased expression of SPP1 mRNA]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
Aluminum Oxide results in decreased secretion of SPP1 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
CTD PMID:19464052 PMID:25216247 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Stath statherin increases expression ISO Aluminum Oxide results in increased expression of STATH mRNA CTD PMID:19464052 NCBI chr14:20,307,324...20,311,182
Ensembl chr14:20,307,324...20,311,182
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression ISO Aluminum Oxide results in increased expression of TGFB1 mRNA CTD PMID:19464052 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tgfbr2 transforming growth factor, beta receptor 2 increases expression ISO Aluminum Oxide results in increased expression of TGFBR2 mRNA CTD PMID:19464052 NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
JBrowse link
G Tnf tumor necrosis factor increases activity
multiple interactions
affects secretion
increases expression
EXP
ISO
Aluminum Oxide results in increased activity of TNF protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased expression of TNF mRNA
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of TNF protein]
Aluminum Oxide affects the secretion of TNF protein
Aluminum Oxide results in increased expression of TNF mRNA
CTD PMID:10413987 PMID:11306444 PMID:15183442 PMID:16488289 PMID:25216247 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf10 TNF superfamily member 10 increases expression ISO Aluminum Oxide analog results in increased expression of TNFSF10 mRNA CTD PMID:23132795 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tp53 tumor protein p53 increases expression ISO Aluminum Oxide analog results in increased expression of TP53 mRNA CTD PMID:23132795 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression ISO Aluminum Oxide results in increased expression of VCAM1 mRNA; Aluminum Oxide results in increased expression of VCAM1 protein CTD PMID:18456438 PMID:19464052 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Aluminum Oxide results in increased expression of VEGFA mRNA CTD PMID:19464052 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vegfb vascular endothelial growth factor B increases expression ISO Aluminum Oxide results in increased expression of VEGFB mRNA CTD PMID:19464052 NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944
JBrowse link
aluminium phosphide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cat catalase decreases expression
decreases activity
EXP aluminum phosphide results in decreased expression of CAT protein
aluminum phosphide results in decreased activity of CAT protein
CTD PMID:11742581 PMID:23041170 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 increases activity EXP aluminum phosphide results in increased activity of G6PC1 protein CTD PMID:20929055 NCBI chr10:86,307,400...86,318,766 JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases activity EXP aluminum phosphide results in decreased activity of G6PD protein CTD PMID:20929055 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Pfkl phosphofructokinase, liver type decreases activity EXP aluminum phosphide results in decreased activity of PFKL protein CTD PMID:20929055 NCBI chr20:10,664,285...10,686,324
Ensembl chr20:10,664,272...10,686,315
JBrowse link
G Pygl glycogen phosphorylase L increases activity EXP aluminum phosphide results in increased activity of PYGL protein CTD PMID:20929055 NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
JBrowse link
G Ren renin increases activity ISO aluminum phosphide results in increased activity of REN protein CTD PMID:2200784 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
aluminium sulfate (anhydrous) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adam9 ADAM metallopeptidase domain 9 decreases expression ISO aluminum sulfate results in decreased expression of ADAM9 mRNA CTD PMID:15961160 NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
JBrowse link
G App amyloid beta precursor protein affects expression
increases expression
ISO aluminum sulfate affects the expression of APP protein
aluminum sulfate results in increased expression of APP mRNA
CTD PMID:10721010 PMID:15961160 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein] CTD PMID:23430110 PMID:24158569 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Ctsb cathepsin B increases expression ISO aluminum sulfate results in increased expression of CTSB protein CTD PMID:24158569 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Daxx death-domain associated protein increases expression ISO aluminum sulfate results in increased expression of DAXX mRNA CTD PMID:15961160 NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
JBrowse link
G Gata2 GATA binding protein 2 decreases expression ISO aluminum sulfate results in decreased expression of GATA2 mRNA CTD PMID:15961160 NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
JBrowse link
G Gtf2h1 general transcription factor IIH subunit 1 decreases expression ISO aluminum sulfate results in decreased expression of GTF2H1 mRNA CTD PMID:15961160 NCBI chr 1:97,321,401...97,349,455
Ensembl chr 1:97,321,394...97,349,455
JBrowse link
G Igf1 insulin-like growth factor 1 increases secretion ISO aluminum sulfate results in increased secretion of IGF1 protein CTD PMID:7685579 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Igf2 insulin-like growth factor 2 increases secretion ISO aluminum sulfate results in increased secretion of IGF2 mRNA; aluminum sulfate results in increased secretion of IGF2 protein CTD PMID:7685579 NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases secretion ISO aluminum sulfate results in decreased secretion of IGFBP3 protein CTD PMID:7685579 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 decreases secretion ISO aluminum sulfate results in decreased secretion of IGFBP4 protein CTD PMID:7685579 NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
JBrowse link
G Il18 interleukin 18 increases expression ISO aluminum sulfate results in increased expression of IL18 protein CTD PMID:16100009 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
ISO aluminum sulfate results in increased expression of IL1B mRNA
[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Sodium inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of IL1B protein]; NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
CTD PMID:15961160 PMID:23430110 PMID:24158569 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions EXP aluminum sulfate inhibits the reaction [Excitatory Amino Acid Agents results in increased metabolism of MAP2 protein] CTD PMID:10428068 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Mapt microtubule-associated protein tau increases phosphorylation EXP aluminum sulfate results in increased phosphorylation of MAPT protein CTD PMID:11388372 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
G Mir146a microRNA 146a multiple interactions ISO [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA] CTD PMID:22099153 NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
JBrowse link
G Mtf1 metal-regulatory transcription factor 1 decreases expression ISO aluminum sulfate results in decreased expression of MTF1 mRNA CTD PMID:15961160 NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
JBrowse link
G Nefl neurofilament light chain decreases expression ISO aluminum sulfate results in decreased expression of NEFL mRNA CTD PMID:15961160 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression
multiple interactions
ISO aluminum sulfate results in increased expression of NFKB1 mRNA
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]
CTD PMID:15961160 PMID:22099153 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein] CTD PMID:24158569 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
JBrowse link
G Nos1 nitric oxide synthase 1 decreases expression EXP aluminum sulfate results in decreased expression of NOS1 protein CTD PMID:10428068 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
JBrowse link
G P2rx1 purinergic receptor P2X 1 decreases expression ISO aluminum sulfate results in decreased expression of P2RX1 mRNA CTD PMID:15961160 NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
JBrowse link
G Pla2g4a phospholipase A2 group IVA increases expression ISO aluminum sulfate results in increased expression of PLA2G4A mRNA CTD PMID:15961160 NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
JBrowse link
G Pml PML nuclear body scaffold multiple interactions ISO [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of PML protein CTD PMID:23430110 NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO aluminum sulfate results in increased expression of PTGS2 mRNA CTD PMID:15961160 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pycard PYD and CARD domain containing multiple interactions ISO PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein] CTD PMID:24158569 NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22099153 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Robo2 roundabout guidance receptor 2 decreases expression ISO aluminum sulfate results in decreased expression of ROBO2 mRNA CTD PMID:15961160 NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536
JBrowse link
G Syn1 synapsin I decreases expression ISO aluminum sulfate results in decreased expression of SYN1 mRNA CTD PMID:15961160 NCBI chr  X:1,172,208...1,227,400
Ensembl chr  X:1,172,208...1,227,396
JBrowse link
G Syp synaptophysin decreases expression ISO aluminum sulfate results in decreased expression of SYP mRNA CTD PMID:15961160 NCBI chr  X:14,849,444...14,864,553
Ensembl chr  X:14,849,444...14,864,745
JBrowse link
aluminium trifluoride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Arf6 ADP-ribosylation factor 6 increases activity ISO aluminum fluoride results in increased activity of ARF6 protein CTD PMID:16280360 NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
JBrowse link
G Cd3e CD3e molecule increases phosphorylation
multiple interactions
ISO aluminum fluoride results in increased phosphorylation of CD3E protein
Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3E protein]
CTD PMID:2824607 NCBI chr 8:45,303,848...45,315,297
Ensembl chr 8:45,303,852...45,315,022
JBrowse link
G Cd3g CD3g molecule multiple interactions
increases phosphorylation
ISO Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3G protein] CTD PMID:2824607 NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
JBrowse link
G Cd79a CD79a molecule increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of CD79A protein CTD PMID:8559152 NCBI chr 1:80,493,520...80,497,936
Ensembl chr 1:80,493,581...80,497,935
JBrowse link
G Cd79b CD79b molecule increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of CD79B protein CTD PMID:8559152 NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625
JBrowse link
G Herc1 HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 affects localization ISO aluminum fluoride affects the localization of HERC1 protein CTD PMID:14960311 NCBI chr 8:66,857,169...67,070,318
Ensembl chr 8:66,856,935...67,070,312
JBrowse link
G Igf2 insulin-like growth factor 2 increases expression ISO aluminum fluoride results in increased expression of IGF2 mRNA; aluminum fluoride results in increased expression of IGF2 protein CTD PMID:11996908 NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 decreases expression ISO aluminum fluoride results in decreased expression of IGFBP4 mRNA; aluminum fluoride results in decreased expression of IGFBP4 protein CTD PMID:11996908 NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 increases expression ISO aluminum fluoride results in increased expression of IGFBP5 mRNA; aluminum fluoride results in increased expression of IGFBP5 protein CTD PMID:11996908 NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of LYN protein CTD PMID:8559152 NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
JBrowse link
G Plcb1 phospholipase C beta 1 multiple interactions EXP PLCB1 protein promotes the reaction [aluminum fluoride results in increased abundance of Inositol Phosphates] CTD PMID:11377826 NCBI chr 3:122,059,968...122,772,896
Ensembl chr 3:122,060,031...122,772,869
JBrowse link
aluminium(0) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity ISO Aluminum results in decreased activity of ACE protein CTD PMID:12008977 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ache acetylcholinesterase multiple interactions
decreases activity
EXP [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein] CTD PMID:15266904 PMID:23354609 PMID:24486960 PMID:29170048 NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO Aluminum results in increased expression of and results in increased activity of ACLY protein CTD PMID:17762189 NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
JBrowse link
G Aco1 aconitase 1 decreases activity EXP Aluminum results in decreased activity of ACO1 protein CTD PMID:10806405 NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
JBrowse link
G Aco2 aconitase 2 decreases activity
multiple interactions
ISO
EXP
Aluminum results in decreased activity of ACO2 protein
Aluminum results in decreased expression of and results in decreased activity of ACO2 protein
Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein]
CTD PMID:12470706 PMID:16906525 PMID:19010380 NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
JBrowse link
G Alb albumin affects binding ISO ALB protein binds to Aluminum CTD PMID:14507469 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions
increases expression
EXP caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]
Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein
CTD PMID:27368151 NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
JBrowse link
G Apob apolipoprotein B increases expression ISO Aluminum results in increased expression of APOB protein CTD PMID:17762189 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
JBrowse link
G App amyloid beta precursor protein affects binding
multiple interactions
increases expression
increases cleavage
ISO
EXP
APP protein binds to Aluminum
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA]
[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA
Aluminum results in increased expression of APP mRNA
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]
CTD PMID:12039845 PMID:16308480 PMID:16724269 PMID:16928369 PMID:16942756 More... NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Atxn3 ataxin 3 affects folding
multiple interactions
ISO Aluminum affects the folding of ATXN3 protein polymorphism
Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]
CTD PMID:17300980 NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects response to substance
multiple interactions
EXP
ISO
BAX protein affects the susceptibility to Aluminum
[aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein
CTD PMID:20385067 PMID:31945389 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbox1 gamma-butyrobetaine hydroxylase 1 multiple interactions
decreases expression
ISO Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
Aluminum results in decreased expression of BBOX1 protein
CTD PMID:21439360 NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein] CTD PMID:31945389 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2L1 protein CTD PMID:31945389 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions
decreases secretion
EXP Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein] CTD PMID:9626627 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Casp12 caspase 12 multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in increased expression of CASP12 mRNA CTD PMID:29635646 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp3 caspase 3 increases expression ISO Aluminum results in increased expression of CASP3 CTD PMID:21972528 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein] CTD PMID:31945389 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Casr calcium-sensing receptor multiple interactions EXP [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein CTD PMID:10231437 NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
JBrowse link
G Cat catalase decreases activity
multiple interactions
ISO
EXP
Aluminum results in decreased activity of CAT protein
CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein]
Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]
CTD PMID:15526171 PMID:17709913 PMID:24486960 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein CTD PMID:32437896 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Chat choline O-acetyltransferase decreases expression
multiple interactions
decreases activity
ISO Aluminum results in decreased expression of CHAT protein
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]
CTD PMID:16724269 PMID:16928369 NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
JBrowse link
G Crp C-reactive protein multiple interactions ISO [Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein CTD PMID:27816692 NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
JBrowse link
G Daxx death-domain associated protein increases expression ISO Aluminum results in increased expression of DAXX mRNA CTD PMID:16308480 NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions EXP Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein] CTD PMID:9109525 NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions EXP Aluminum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] CTD PMID:9109525 NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
JBrowse link
G Eno2 enolase 2 decreases activity ISO Aluminum results in decreased activity of ENO2 protein CTD PMID:11860913 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
JBrowse link
G Epor erythropoietin receptor affects expression ISO Aluminum affects the expression of EPOR protein CTD PMID:15777837 NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein CTD PMID:31945389 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein CTD PMID:31945389 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G F8 coagulation factor VIII affects folding
multiple interactions
ISO Aluminum affects the folding of F8 protein
[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein
CTD PMID:15349964 NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
JBrowse link
G Fh fumarate hydratase multiple interactions ISO Aluminum results in decreased expression of and results in decreased activity of FH protein CTD PMID:16906525 NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein] CTD PMID:23690655 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases activity ISO
EXP
Aluminum results in increased activity of G6PD protein CTD PMID:16572710 PMID:16979867 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gfap glial fibrillary acidic protein increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of GFAP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]
CTD PMID:16545059 PMID:31363819 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Gnai1 G protein subunit alpha i1 decreases expression EXP Aluminum results in decreased expression of GNAI1 protein CTD PMID:9626627 NCBI chr 4:16,813,941...16,898,111
Ensembl chr 4:16,814,001...16,896,417
JBrowse link
G Gnai2 G protein subunit alpha i2 decreases expression EXP Aluminum results in decreased expression of GNAI2 protein CTD PMID:9626627 NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
JBrowse link
G Gnaq G protein subunit alpha q increases response to substance ISO GNAQ protein results in increased susceptibility to Aluminum CTD PMID:15068510 NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO Aluminum results in increased expression of and results in increased activity of GPD1 protein CTD PMID:17762189 NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
JBrowse link
G Gpx1 glutathione peroxidase 1 decreases activity
multiple interactions
ISO Aluminum results in decreased activity of GPX1 protein
Vitamin E inhibits the reaction [Aluminum results in decreased activity of GPX1 protein]
CTD PMID:17709913 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G Gsr glutathione-disulfide reductase decreases expression
multiple interactions
EXP Aluminum results in decreased expression of GSR protein
Plant Extracts inhibits the reaction [Aluminum results in decreased expression of GSR protein]
CTD PMID:24486960 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases localization ISO Aluminum results in increased localization of HIF1A protein CTD PMID:16979867 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hk1 hexokinase 1 multiple interactions
decreases activity
EXP Meclofenoxate inhibits the reaction [Aluminum results in decreased activity of HK1 protein] CTD PMID:16969689 NCBI chr20:30,230,488...30,332,161
Ensembl chr20:30,230,486...30,332,131
JBrowse link
G Idh1 isocitrate dehydrogenase (NADP(+)) 1 decreases activity EXP Aluminum results in decreased activity of IDH1 protein CTD PMID:15486972 NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 decreases activity EXP Aluminum results in decreased activity of IDH2 protein CTD PMID:15486972 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA] CTD PMID:23690655 NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein] CTD PMID:14745455 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Il12b interleukin 12B multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA] CTD PMID:23690655 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
EXP [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein] CTD PMID:16545059 PMID:27368151 PMID:29170048 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il4 interleukin 4 increases expression ISO Aluminum results in increased expression of IL4 mRNA CTD PMID:16630673 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
EXP
ISO
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein]
[Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein
CTD PMID:27368151 PMID:27816692 PMID:29170048 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein] CTD PMID:23690655 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Klk1 kallikrein 1 multiple interactions ISO Aluminum binds to and results in decreased activity of KLK1 protein CTD PMID:15558947 NCBI chr 1:94,642,722...94,646,714
Ensembl chr 1:94,642,687...94,646,754
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor multiple interactions ISO [Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of LITAF mRNA CTD PMID:17408380 NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
JBrowse link
G Lonrf2 LON peptidase N-terminal domain and ring finger 2 decreases expression EXP Aluminum results in decreased expression of LONRF2 mRNA CTD PMID:19010380 NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein CTD PMID:16728372 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapt microtubule-associated protein tau increases phosphorylation
multiple interactions
EXP Aluminum results in increased phosphorylation of MAPT protein
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
CTD PMID:17662457 PMID:29170048 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
G Mir21 microRNA 21 multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR21 mRNA CTD PMID:27506416 NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
JBrowse link
G Mir30d microRNA 30d multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR30D mRNA CTD PMID:27506416 NCBI chr 7:100,136,391...100,136,472
Ensembl chr 7:100,136,391...100,136,472
JBrowse link
G Mir322 microRNA 322 multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR424 mRNA CTD PMID:27506416 NCBI chr  X:132,806,594...132,806,688 JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression EXP Aluminum results in increased expression of MMP2 protein CTD PMID:16052892 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mmp7 matrix metallopeptidase 7 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP7 mRNA CTD PMID:32437896 NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of MMP9 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA
CTD PMID:16052892 PMID:32437896 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Mpo myeloperoxidase increases expression ISO Aluminum results in increased expression of MPO protein CTD PMID:17402216 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form] CTD PMID:14745455 PMID:26989453 NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP
ISO
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]
CTD PMID:16728372 PMID:23690655 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nrg1 neuregulin 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein] CTD PMID:31945389 NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions
increases activity
ISO
EXP
Aluminum results in decreased expression of and results in decreased activity of OGDH protein
Aluminum results in increased activity of OGDH protein
CTD PMID:10806405 PMID:16906525 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Oprd1 opioid receptor, delta 1 multiple interactions EXP [Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in decreased abundance of Aluminum CTD PMID:7477890 NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of PCK1 protein CTD PMID:31945389 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in decreased expression of PCNA mRNA CTD PMID:29635646 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pklr pyruvate kinase L/R increases activity ISO Aluminum results in increased activity of PKLR protein CTD PMID:16979867 NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
JBrowse link
G Plcd1 phospholipase C, delta 1 increases expression EXP Aluminum results in increased expression of PLCD1 protein CTD PMID:10814511 NCBI chr 8:118,795,196...118,818,186
Ensembl chr 8:118,795,201...118,818,186
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]
CTD PMID:16928369 PMID:23690655 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pth parathyroid hormone multiple interactions ISO [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein CTD PMID:10978387 NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
JBrowse link
G Rcvrn recoverin multiple interactions ISO [APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA CTD PMID:21298039 NCBI chr10:52,388,706...52,396,454
Ensembl chr10:52,388,706...52,396,453
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] CTD PMID:23690655 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rpl37 ribosomal protein L37 decreases expression ISO Aluminum results in decreased expression of RPL37 mRNA; Aluminum results in decreased expression of RPL37 protein CTD PMID:27329587 NCBI chr10:61,033,799...61,034,157
Ensembl chr10:61,033,797...61,034,168
JBrowse link
G S100b S100 calcium binding protein B increases expression
multiple interactions
EXP Aluminum results in increased expression of S100B protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of S100B protein]
CTD PMID:16545059 NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
JBrowse link
G Scgb1a1 secretoglobin family 1A member 1 decreases expression EXP
ISO
Aluminum results in decreased expression of SCGB1A1 protein CTD PMID:16052892 PMID:16099050 NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610
JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Aluminum results in increased expression of SLC2A1 protein CTD PMID:16979867 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein CTD PMID:32437896 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
JBrowse link
G Snca synuclein alpha affects response to substance ISO SNCA protein affects the susceptibility to Aluminum CTD PMID:23106139 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
JBrowse link
G Sod2 superoxide dismutase 2 decreases activity EXP Aluminum results in decreased activity of SOD2 protein CTD PMID:19010380 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Tf transferrin multiple interactions
increases uptake
affects binding
ISO [Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum
TF protein results in increased uptake of Aluminum
Aluminum binds to TF protein; TF protein binds to Aluminum
TRF protein binds to Aluminum
CTD PMID:1375080 PMID:2039817 PMID:2308257 PMID:8782865 PMID:10978387 More... NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
JBrowse link
G Tfrc transferrin receptor decreases expression
affects uptake
EXP Aluminum results in decreased expression of TFRC mRNA
TFRC protein affects the uptake of Aluminum
CTD PMID:9630424 PMID:11068183 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TGFB1 mRNA CTD PMID:32437896 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of TNF protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein]
[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA
CTD PMID:16545059 PMID:17408380 PMID:23690655 PMID:27368151 PMID:29170048 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of TUBB3 protein CTD PMID:31363819 NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
JBrowse link
G Txn2 thioredoxin 2 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of TXN2 protein CTD PMID:31945389 NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
JBrowse link
G Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 decreases expression ISO Aluminum results in decreased expression of UBA52 mRNA; Aluminum results in decreased expression of UBA52 protein CTD PMID:27329587 NCBI chr16:18,918,614...18,920,807 JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein CTD PMID:32437896 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vim vimentin multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein CTD PMID:32437896 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
G Xdh xanthine dehydrogenase increases activity EXP Aluminum results in increased activity of XDH protein CTD PMID:11787993 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
boric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme multiple interactions ISO boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] CTD PMID:28544013 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO boric acid results in decreased expression of ACTA2 protein CTD PMID:25637568 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] CTD PMID:28285642 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Agt angiotensinogen multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA] CTD PMID:28285642 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases expression ISO boric acid results in increased expression of AKT1 mRNA CTD PMID:31368021 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Arg1 arginase 1 decreases activity ISO boric acid results in decreased activity of ARG1 protein CTD PMID:21232540 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein CTD PMID:25425213 PMID:27587023 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO boric acid results in increased cleavage of and affects the localization of ATF6 protein CTD PMID:27587023 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression
multiple interactions
ISO
EXP
boric acid results in decreased expression of BAX mRNA
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein
CTD PMID:31368021 PMID:33137424 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions
ISO
EXP
boric acid results in increased expression of BCL2 mRNA
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein
CTD PMID:31368021 PMID:33137424 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Calr calreticulin increases expression ISO boric acid results in increased expression of CALR mRNA CTD PMID:27587023 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
JBrowse link
G Casp3 caspase 3 decreases expression
multiple interactions
ISO boric acid results in decreased expression of CASP3 mRNA
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]
CTD PMID:31368021 PMID:31823256 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions
decreases activity
EXP
ISO
[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]
CTD PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]
boric acid results in increased expression of CCND1 mRNA
CTD PMID:28285642 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]] CTD PMID:28285642 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA] CTD PMID:28285642 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Col1a2 collagen type I alpha 2 chain affects expression ISO boric acid affects the expression of COL1A2 mRNA CTD PMID:24704097 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Csf2 colony stimulating factor 2 increases expression ISO boric acid results in increased expression of CSF2 protein CTD PMID:27206737 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO boric acid results in increased expression of CSF3 protein CTD PMID:27206737 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 decreases expression ISO boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein CTD PMID:27587023 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Des desmin affects expression ISO boric acid affects the expression of DES mRNA CTD PMID:25637568 NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
JBrowse link
G Dvl2 dishevelled segment polarity protein 2 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA] CTD PMID:28285642 NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 increases expression ISO boric acid results in increased expression of EDEM1 mRNA CTD PMID:27587023 NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] CTD PMID:30196486 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation
multiple interactions
ISO boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]
CTD PMID:25425213 PMID:27587023 PMID:30196486 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]] CTD PMID:28285642 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA] CTD PMID:28285642 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein] CTD PMID:28285642 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Fgf7 fibroblast growth factor 7 increases expression ISO boric acid results in increased expression of FGF7 protein CTD PMID:27206737 NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
JBrowse link
G Fn1 fibronectin 1 increases expression
affects expression
ISO boric acid results in increased expression of FN1 mRNA
boric acid affects the expression of FN1 mRNA
CTD PMID:27206737 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO boric acid results in decreased expression of GAPDH protein CTD PMID:28285642 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
JBrowse link
G Gas6 growth arrest specific 6 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein] CTD PMID:28285642 NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
JBrowse link
G Gck glucokinase increases expression ISO boric acid results in increased expression of GCK mRNA CTD PMID:31368021 NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
ISO EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA] CTD PMID:30196486 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression ISO boric acid results in increased expression of HERPUD1 mRNA CTD PMID:27587023 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO boric acid results in increased expression of HMOX1 mRNA CTD PMID:30196486 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hoxa6 homeobox A6 affects expression EXP boric acid affects the expression of HOXA6 mRNA CTD PMID:12749385 NCBI chr 4:81,304,918...81,313,184
Ensembl chr 4:81,306,407...81,308,850
JBrowse link
G Hoxc6 homeo box C6 affects expression EXP boric acid affects the expression of HOXC6 mRNA CTD PMID:12749385 NCBI chr 7:134,138,017...134,148,899 JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein CTD PMID:25425213 PMID:27587023 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Ifng interferon gamma multiple interactions EXP [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein] CTD PMID:29913234 PMID:30368975 PMID:33137424 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] CTD PMID:30997025 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] CTD PMID:29913234 PMID:30368975 PMID:30997025 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions EXP [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein CTD PMID:33137424 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il4 interleukin 4 increases expression
multiple interactions
ISO
EXP
boric acid results in increased expression of IL4 mRNA
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein
CTD PMID:31368021 PMID:33137424 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]
CTD PMID:28285642 PMID:30997025 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions
increases expression
ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA
CTD PMID:28285642 PMID:31368021 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Klf5 Kruppel-like factor 5 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA] CTD PMID:28285642 NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
JBrowse link
G Lama5 laminin subunit alpha 5 increases expression ISO boric acid results in increased expression of LAMA5 mRNA CTD PMID:27206737 NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
JBrowse link
G Lep leptin multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein CTD PMID:28285642 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lipe lipase E, hormone sensitive type multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA] CTD PMID:28285642 NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein] CTD PMID:28285642 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:28285642 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression ISO boric acid results in decreased expression of MMP2 protein CTD PMID:28285642 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Myh1 myosin heavy chain 1 affects expression ISO boric acid affects the expression of MYH1 mRNA CTD PMID:25637568 NCBI chr10:51,885,913...51,909,699 JBrowse link
G Myod1 myogenic differentiation 1 affects expression
decreases expression
ISO boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein
CTD PMID:25637568 NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
JBrowse link
G Myog myogenin affects expression ISO boric acid affects the expression of MYOG mRNA CTD PMID:25637568 NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects localization
multiple interactions
ISO boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]
CTD PMID:30196486 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
affects expression
ISO boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA
CTD PMID:31823256 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:27206737 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO boric acid results in increased expression of NQO1 mRNA CTD PMID:30196486 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression
multiple interactions
EXP boric acid results in increased expression of PCNA protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA
CTD PMID:17943231 PMID:33137424 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 increases expression ISO boric acid results in increased expression of PDX1 mRNA CTD PMID:31368021 NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein CTD PMID:27587023 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] CTD PMID:27206737 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein] CTD PMID:29913234 PMID:30368975 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Runx2 RUNX family transcription factor 2 affects expression ISO boric acid affects the expression of RUNX2 mRNA CTD PMID:24704097 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases expression ISO boric acid results in increased expression of SLC2A2 mRNA CTD PMID:31368021 NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] CTD PMID:28285642 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slc4a2 solute carrier family 4 member 2 increases expression ISO boric acid results in increased expression of SLC4A2 mRNA CTD PMID:22576912 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
JBrowse link
G Slc4a3 solute carrier family 4 member 3 increases expression ISO boric acid results in increased expression of SLC4A3 mRNA CTD PMID:22576912 NCBI chr 9:77,036,243...77,053,940
Ensembl chr 9:77,037,016...77,049,105
JBrowse link
G Sparc secreted protein acidic and cysteine rich affects expression ISO boric acid affects the expression of SPARC mRNA CTD PMID:24704097 NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:28285642 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Syvn1 synoviolin 1 decreases expression ISO boric acid results in decreased expression of SYVN1 mRNA CTD PMID:27587023 NCBI chr 1:203,339,235...203,346,137
Ensembl chr 1:203,339,619...203,346,152
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression ISO boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA
CTD PMID:27206737 PMID:31368021 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
increases secretion
increases expression
ISO
EXP
boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA
CTD PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein] CTD PMID:28285642 NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
JBrowse link
G Tp53 tumor protein p53 decreases expression ISO boric acid results in decreased expression of TRP53 mRNA CTD PMID:31368021 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO boric acid results in increased expression of XBP1 mRNA CTD PMID:27587023 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
JBrowse link
boric acids term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ggt1 gamma-glutamyltransferase 1 decreases activity EXP Boric Acids analog results in decreased activity of GGT1 protein CTD PMID:6149445 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Boric Acids results in decreased expression of MUC1 mRNA CTD PMID:21060261 NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
JBrowse link
G Muc16 mucin 16, cell surface associated decreases expression ISO Boric Acids results in decreased expression of MUC16 mRNA CTD PMID:21060261 NCBI chr 8:16,164,531...16,323,126 JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca2 ATP binding cassette subfamily A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases expression
decreases activity
ISO [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein
CTD PMID:25576094 PMID:30482226 PMID:33775688 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein
CTD PMID:20977926 PMID:33775688 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061
JBrowse link
G Abi1 abl-interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284 PMID:17495969 PMID:21195056 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309
JBrowse link
G Adam10 ADAM metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA
CTD PMID:20471514 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G Aff1 AF4/FMR2 family, member 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729
JBrowse link
G Aff4 AF4/FMR2 family, member 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751
JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934
JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
JBrowse link
G Agtpbp1 ATP/GTP binding carboxypeptidase 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr17:5,120,540...5,238,874
Ensembl chr17:5,120,609...5,238,869
JBrowse link
G Agtrap angiotensin II receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 affects localization
multiple interactions
ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
CTD PMID:12893773 PMID:16024631 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Aifm2 apoptosis inducing factor, mitochondria associated 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr20:29,654,283...29,679,239
Ensembl chr20:29,652,927...29,679,236
JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 increases expression EXP Bortezomib results in increased expression of AKR1B8 mRNA CTD PMID:20830808 NCBI chr 4:62,997,241...63,009,815 JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein
CTD PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
JBrowse link
G Aldh6a1 aldehyde dehydrogenase 6 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr10:105,875,209...105,886,307 JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression
ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA
CTD PMID:17895889 PMID:20977926 NCBI chr12:33,748,714...33,781,709
Ensembl chr12:33,748,735...33,781,781
JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923
JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 1:95,384,303...95,414,249
Ensembl chr 1:95,384,309...95,414,147
JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 1:181,168,982...181,173,528
Ensembl chr 1:181,168,916...181,173,528
JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:77,377,685...77,443,670
Ensembl chr  X:77,377,781...77,443,900
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796 PMID:30818834 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arf6 ADP-ribosylation factor 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
JBrowse link
G Arfgap1 ADP-ribosylation factor GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933
JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318
JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513
JBrowse link
G Arl8a ADP-ribosylation factor like GTPase 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr13:46,585,845...46,594,851
Ensembl chr13:46,585,845...46,594,851
JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression
ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA
CTD PMID:12393500 PMID:20977926 NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions
ISO
EXP
ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
CTD PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16928686 PMID:20022965 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases cleavage
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Atp1a3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
JBrowse link
G Atp2a1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib
CTD PMID:25576094 NCBI chr 1:181,026,606...181,044,859 JBrowse link
G Atp6v0e1 ATPase H+ transporting V0 subunit e1 increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273
JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247
JBrowse link
G Bag3 BAG cochaperone 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775 PMID:17659339 PMID:20471514 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression
ISO [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein
CTD PMID:12902978 PMID:17326159 PMID:20850924 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein
CTD PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295 PMID:20051518 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bbln bublin coiled coil protein decreases expression ISO Bortezomib results in decreased expression of BBLN mRNA CTD PMID:20977926 NCBI chr 3:15,674,577...15,677,393
Ensembl chr 3:15,674,580...15,677,374
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
CTD PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More... NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions
increases expression
ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein
CTD PMID:18223231 PMID:20051518 NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib
CTD PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More... NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
increases activity
increases response to substance
ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib
CTD PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA
CTD PMID:20471514 PMID:20977926 NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
JBrowse link
G Bcl6 BCL6, transcription repressor increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
JBrowse link
G Bcl7a BAF chromatin remodeling complex subunit BCL7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:33,211,978...33,243,886
Ensembl chr12:33,223,931...33,243,886
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr20:13,471,679...13,596,497
Ensembl chr20:13,471,668...13,597,016
JBrowse link
G Becn1 beclin 1 multiple interactions
decreases response to substance
ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib
CTD PMID:22842577 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions
ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
CTD PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More... NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity
ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein
CTD PMID:16446371 PMID:18566236 NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
CTD PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
CTD PMID:17626072 PMID:24085292 PMID:25522274 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression
ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein
Bortezomib results in increased expression of BIRC5 protein
CTD PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More... NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
JBrowse link
G Bles03 basophilic leukemia expressed protein BLES03 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804
JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031
JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination
ISO Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein
CTD PMID:21917757 PMID:25522274 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA
CTD PMID:21917757 PMID:25913414 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex, subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080
JBrowse link
G Brf2 BRF2, RNA polymerase III transcription initiation factor subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr16:64,928,334...64,933,057
Ensembl chr16:64,928,300...64,933,059
JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092
JBrowse link
G Ca9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
JBrowse link
G Calr calreticulin multiple interactions
increases expression
ISO [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
CTD PMID:30482226 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508
JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237
JBrowse link
G Casp12 caspase 12 increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775 PMID:16357177 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage
ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein
CTD PMID:15509775 PMID:16446371 PMID:18723477 NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression
ISO Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein
CTD PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity
ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein
CTD PMID:16357177 PMID:18641367 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327 PMID:17510429 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein
CTD PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More... NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
CTD PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More... NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cbl Cbl proto-oncogene multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176
JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931 PMID:20977926 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283
JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647 PMID:21903591 NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935
JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 3:105,998,429...106,010,930
Ensembl chr 3:105,998,430...106,010,975
JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression
EXP
ISO
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA
CTD PMID:18089816 PMID:20830808 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein
CTD PMID:19074855 PMID:20367638 PMID:25522274 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein] CTD PMID:12893773 PMID:15173093 PMID:15781649 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514 PMID:20977926 NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
JBrowse link
G Cd27 CD27 molecule increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
JBrowse link
G Cd38 CD38 molecule decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
JBrowse link
G Cd69 Cd69 molecule increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
JBrowse link
G Cd79a CD79a molecule decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 1:80,493,520...80,497,936
Ensembl chr 1:80,493,581...80,497,935
JBrowse link
G Cd82 Cd82 molecule decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
JBrowse link
G Cd9 CD9 molecule increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
JBrowse link
G Cdc23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186
JBrowse link
G Cdc37 cell division cycle 37, HSP90 cochaperone increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein
CTD PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein
CTD PMID:14749476 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression
ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
CTD PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 More... NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression
ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein
CTD PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 More... NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
decreases expression
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib results in decreased expression of CEBPB mRNA
CTD PMID:20471514 PMID:20830808 PMID:30482226 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cenpc centromere protein C increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476
JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr 7:35,310,071...35,399,392
Ensembl chr 7:35,310,199...35,399,392
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression
ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
CTD PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 More... NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
JBrowse link
G Chaf1a chromatin assembly factor 1 subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014
JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111
JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 8:95,960,067...95,965,803
Ensembl chr 8:95,959,826...95,966,955
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases expression
increases activity
ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein
CTD PMID:20471514 PMID:24085292 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr15:29,252,203...29,256,759
Ensembl chr15:29,252,213...29,256,605
JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691
JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr 6:23,616,280...23,697,625
Ensembl chr 6:23,616,281...23,677,874
JBrowse link
G Cln6 CLN6, transmembrane ER protein decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360
JBrowse link
G Clptm1 CLPTM1 regulator of GABA type A receptor forward trafficking decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092
JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:204,402,118...204,404,439 JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c increases response to substance ISO CPT1C gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
JBrowse link
G Crebbp CREB binding protein decreases expression ISO Bortezomib results in decreased expression of CREBBP mRNA CTD PMID:25913414 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
JBrowse link
G Crem cAMP responsive element modulator increases expression ISO Bortezomib results in increased expression of CREM mRNA CTD PMID:20977926 NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
JBrowse link
G Crip2 cysteine-rich protein 2 decreases expression ISO Bortezomib results in decreased expression of CRIP2 mRNA CTD PMID:20977926 NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
JBrowse link
G Cryab crystallin, alpha B multiple interactions
increases expression
ISO
EXP
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA
CTD PMID:20830808 PMID:25522274 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Cst7 cystatin F increases expression ISO Bortezomib results in increased expression of CST7 mRNA CTD PMID:20977926 NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557
JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression ISO Bortezomib results in decreased expression of CTDSPL2 mRNA CTD PMID:20977926 NCBI chr 3:108,914,650...108,970,620
Ensembl chr 3:108,915,280...108,967,227
JBrowse link
G Cth cystathionine gamma-lyase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA CTD PMID:25522274 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases response to substance
increases expression
ISO 2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] CTD PMID:18485479 PMID:19100720 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Ctsb cathepsin B multiple interactions
increases localization
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] CTD PMID:16446371 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Ctsd cathepsin D increases expression ISO Bortezomib results in increased expression of CTSD mRNA CTD PMID:20977926 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Cul1 cullin 1 increases expression ISO Bortezomib results in increased expression of CUL1 mRNA CTD PMID:17895889 NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
JBrowse link
G Cul3 cullin 3 decreases expression ISO Bortezomib results in decreased expression of CUL3 mRNA CTD PMID:17659339 NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
JBrowse link
G Cwf19l1 CWF19 like cell cycle control factor 1 decreases expression ISO Bortezomib results in decreased expression of CWF19L1 mRNA CTD PMID:20977926 NCBI chr 1:242,997,720...243,020,989
Ensembl chr 1:242,997,726...243,020,961
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Bortezomib results in increased expression of CXCL1 mRNA CTD PMID:15509775 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]
CTD PMID:20830808 PMID:27194111 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression
ISO Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA
CTD PMID:15509775 PMID:27194111 NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Bortezomib results in decreased expression of CXCR4 mRNA CTD PMID:20977926 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO Bortezomib results in increased expression of CYB5R1 mRNA CTD PMID:20977926 NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression ISO Bortezomib results in decreased expression of CYBA mRNA CTD PMID:20977926 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cycs cytochrome c, somatic multiple interactions
affects localization
ISO [Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein
CTD PMID:12893773 PMID:16024631 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 affects metabolic processing ISO CYP2C19 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO Bortezomib results in increased expression of CYP2U1 mRNA CTD PMID:20977926 NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cytip cytohesin 1 interacting protein increases expression ISO Bortezomib results in increased expression of CYTIP mRNA CTD PMID:20977926 NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
JBrowse link
G Dap3 death associated protein 3 increases expression ISO Bortezomib results in increased expression of DAP3 mRNA CTD PMID:17659339 NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
JBrowse link
G Dapk2 death-associated protein kinase 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA CTD PMID:25522274 NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567
JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression ISO Bortezomib results in decreased expression of DAZAP2 mRNA CTD PMID:20977926 NCBI chr 7:131,714,723...131,720,266
Ensembl chr 7:131,714,745...131,720,265
JBrowse link
G Dbn1 drebrin 1 increases expression ISO Bortezomib results in increased expression of DBN1 mRNA CTD PMID:20977926 NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
JBrowse link
G Dcaf11 DDB1 and CUL4 associated factor 11 decreases expression ISO Bortezomib results in decreased expression of DCAF11 mRNA CTD PMID:20977926 NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669
JBrowse link
G Dcaf13 DDB1 and CUL4 associated factor 13 increases expression ISO Bortezomib results in increased expression of DCAF13 mRNA CTD PMID:20977926 NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142
JBrowse link
G Dcps decapping enzyme, scavenger decreases expression ISO Bortezomib results in decreased expression of DCPS mRNA CTD PMID:20977926 NCBI chr 8:33,468,669...33,524,407 JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
decreases response to substance
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 More... NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Ddx11 DEAD/H-box helicase 11 decreases expression ISO Bortezomib results in decreased expression of DDX11 mRNA CTD PMID:20977926 NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550
JBrowse link
G Deaf1 DEAF1 transcription factor decreases expression ISO Bortezomib results in decreased expression of DEAF1 mRNA CTD PMID:20977926 NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541
JBrowse link
G Dedd2 death effector domain containing 2 increases expression ISO Bortezomib results in increased expression of DEDD2 mRNA CTD PMID:17659339 NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714
JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor decreases expression ISO Bortezomib results in decreased expression of DEF6 mRNA CTD PMID:20977926 NCBI chr20:6,268,614...6,290,030
Ensembl chr20:6,268,601...6,289,961
JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO Bortezomib results in increased expression of DENND4A mRNA CTD PMID:20977926 NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330
JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO Bortezomib results in increased expression of DENND4B mRNA CTD PMID:15509775 NCBI chr 2:175,720,473...175,736,425
Ensembl chr 2:175,709,610...175,736,426
JBrowse link
G Dennd4c DENN domain containing 4C increases expression ISO Bortezomib results in increased expression of DENND4C mRNA CTD PMID:20977926 NCBI chr 5:101,272,298...101,369,529
Ensembl chr 5:101,272,005...101,368,118
JBrowse link
G Dgke diacylglycerol kinase epsilon decreases expression ISO Bortezomib results in decreased expression of DGKE mRNA CTD PMID:20977926 NCBI chr10:73,852,679...73,877,334
Ensembl chr10:73,855,583...73,877,100
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases localization
increases expression
multiple interactions
ISO Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]
CTD PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 More... NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G Dlgap5 DLG associated protein 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA CTD PMID:25522274 NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
JBrowse link
G Dnaaf5 dynein, axonemal, assembly factor 5 decreases expression ISO Bortezomib results in decreased expression of DNAAF5 mRNA CTD PMID:20977926 NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO Bortezomib results in increased expression of DNAJB1 mRNA CTD PMID:15509775 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Dnajc14 DnaJ heat shock protein family (Hsp40) member C14 decreases expression ISO Bortezomib results in decreased expression of DNAJC14 mRNA CTD PMID:20977926 NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645
JBrowse link
G Dnajc4 DnaJ heat shock protein family (Hsp40) member C4 decreases expression ISO Bortezomib results in decreased expression of DNAJC4 mRNA CTD PMID:20977926 NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387
JBrowse link
G Dnm2 dynamin 2 decreases expression ISO Bortezomib results in decreased expression of DNM2 mRNA CTD PMID:20977926 NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
JBrowse link
G Dpy19l4 dpy-19 like 4 increases expression ISO Bortezomib results in increased expression of DPY19L4 mRNA CTD PMID:20977926 NCBI chr 5:24,351,289...24,410,932
Ensembl chr 5:24,353,900...24,410,912
JBrowse link
G Dst dystonin increases expression ISO Bortezomib results in increased expression of DST mRNA CTD PMID:17659339 NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
JBrowse link
G Dusp15 dual specificity phosphatase 15 decreases expression ISO Bortezomib results in decreased expression of DUSP15 mRNA CTD PMID:20977926 NCBI chr 3:141,408,495...141,419,137
Ensembl chr 3:141,408,498...141,418,999
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Bortezomib results in decreased expression of DUSP4 mRNA CTD PMID:20977926 NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA CTD PMID:25522274 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression ISO Bortezomib results in increased expression of DYNC1I1 mRNA CTD PMID:20977926 NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein CTD PMID:25522274 NCBI chr 3:143,064,535...143,075,362 JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold increases expression ISO Bortezomib results in increased expression of ECPAS mRNA CTD PMID:20977926 NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
JBrowse link
G Edaradd EDAR-associated death domain increases expression ISO Bortezomib results in increased expression of EDARADD mRNA CTD PMID:17895889 NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA CTD PMID:25522274 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
JBrowse link
G Egr1 early growth response 1 increases expression ISO Bortezomib results in increased expression of EGR1 mRNA CTD PMID:20471514 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Egr2 early growth response 2 decreases expression ISO
EXP
Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein
CTD PMID:20830808 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of EHMT2 mRNA CTD PMID:20977926 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
JBrowse link
G Eif1 eukaryotic translation initiation factor 1 increases expression ISO Bortezomib results in increased expression of EIF1 mRNA CTD PMID:20977926 NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A decreases phosphorylation ISO Bortezomib results in decreased phosphorylation of EIF2A protein CTD PMID:18641367 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation
multiple interactions
decreases response to substance
ISO Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16928686 PMID:20022965 PMID:22959925 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions
increases phosphorylation
ISO Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] CTD PMID:16357177 PMID:20022965 PMID:21090173 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Eif2s3 eukaryotic translation initiation factor 2 subunit gamma decreases expression ISO Bortezomib results in decreased expression of EIF2S3 mRNA CTD PMID:20977926 NCBI chr  X:58,916,513...58,939,923
Ensembl chr  X:58,917,490...58,940,686
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:21345073 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Eif5a eukaryotic translation initiation factor 5A decreases expression ISO Bortezomib results in decreased expression of EIF5A mRNA CTD PMID:20977926 NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
JBrowse link
G Elp5 elongator acetyltransferase complex subunit 5 decreases expression ISO Bortezomib results in decreased expression of ELP5 mRNA CTD PMID:20977926 NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923
JBrowse link
G Eno2 enolase 2 increases expression ISO Bortezomib results in increased expression of ENO2 mRNA CTD PMID:20977926 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
JBrowse link
G Epha1 Eph receptor A1 decreases expression ISO Bortezomib results in decreased expression of EPHA1 mRNA CTD PMID:20977926 NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
JBrowse link
G Ephb2 Eph receptor B2 decreases expression ISO Bortezomib results in decreased expression of EPHB2 mRNA CTD PMID:20977926 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
ISO Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
JBrowse link
G Ercc3 ERCC excision repair 3, TFIIH core complex helicase subunit increases response to substance ISO ERCC3 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases response to substance ISO ERCC4 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:2,416,259...2,448,364 JBrowse link
G Erlin2 ER lipid raft associated 2 decreases expression ISO Bortezomib results in decreased expression of ERLIN2 mRNA CTD PMID:20977926 NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
decreases response to substance
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA
ERN1 results in decreased susceptibility to Bortezomib
CTD PMID:16357177 PMID:25522274 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
JBrowse link
G Esf1 ESF1 nucleolar pre-rRNA processing protein homolog increases expression ISO Bortezomib results in increased expression of ESF1 mRNA CTD PMID:20977926 NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:25752796 PMID:30818834 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:25752796 PMID:25913414 PMID:30818834 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Esrra estrogen related receptor, alpha decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
CTD PMID:20977926 PMID:30818834 NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
JBrowse link
G Esyt2 extended synaptotagmin 2 decreases expression ISO Bortezomib results in decreased expression of ESYT2 mRNA CTD PMID:20977926 NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590
JBrowse link
G Etv4 ETS variant transcription factor 4 decreases expression ISO Bortezomib results in decreased expression of ETV4 mRNA CTD PMID:20977926 NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974
JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression ISO Bortezomib results in decreased expression of F2RL1 mRNA CTD PMID:20977926 NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions
ISO Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein
CTD PMID:23696885 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Bortezomib results in decreased expression of FADS2 mRNA CTD PMID:20977926 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
JBrowse link
G Faf1 Fas associated factor 1 increases expression ISO Bortezomib results in increased expression of FAF1 mRNA CTD PMID:17895889 NCBI chr 5:124,426,032...124,790,014
Ensembl chr 5:124,426,062...124,789,977
JBrowse link
G Fam118b family with sequence similarity 118, member B increases expression ISO Bortezomib results in increased expression of FAM118B mRNA CTD PMID:20977926 NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270
JBrowse link
G Fam168a family with sequence similarity 168, member A increases expression ISO Bortezomib results in increased expression of FAM168A mRNA CTD PMID:20977926 NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220
JBrowse link
G Fam20b FAM20B, glycosaminoglycan xylosylkinase decreases expression ISO Bortezomib results in decreased expression of FAM20B mRNA CTD PMID:20977926 NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915
JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression ISO Bortezomib results in increased expression of FAM219A mRNA CTD PMID:20977926 NCBI chr 5:56,679,272...56,729,959
Ensembl chr 5:56,680,613...56,729,924
JBrowse link
G Fam241b family with sequence similarity 241 member B increases expression ISO Bortezomib results in increased expression of FAM241B mRNA CTD PMID:20977926 NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
JBrowse link
G Fam43a family with sequence similarity 43, member A decreases expression ISO Bortezomib results in decreased expression of FAM43A mRNA CTD PMID:20977926 NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
JBrowse link
G Fam76a family with sequence similarity 76, member A increases expression ISO Bortezomib results in increased expression of FAM76A mRNA CTD PMID:20977926 NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574
JBrowse link
G Fancd2 FA complementation group D2 decreases expression ISO Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein CTD PMID:19934314 PMID:21917757 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
JBrowse link
G Farsa phenylalanyl-tRNA synthetase subunit alpha decreases expression ISO Bortezomib results in decreased expression of FARSA mRNA CTD PMID:20977926 NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
decreases expression
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein
CTD PMID:17351739 PMID:20471514 PMID:25913414 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Faslg Fas ligand multiple interactions
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein
CTD PMID:17351739 PMID:20471514 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fastk Fas-activated serine/threonine kinase decreases expression ISO Bortezomib results in decreased expression of FASTK mRNA CTD PMID:20977926 NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
JBrowse link